Momenta’s failed pancreatic cancer drug is given a midnight funeral
Pancreatic cancer has claimed another biotech victim. The tough oncology target proved resistant to Momenta Pharmaceuticals’ necuparanib at the halfway point in their Phase II study. And now the biotech $MNTA has decided to deep-six the drug and move on, according to an SEC filing.
Momenta’s 8-K, filed on Thursday, states:
After confirming the results of the futility analysis and reviewing the unblinded safety and efficacy data and the results of various sensitivity and subgroup analyses, the company decided to discontinue the necuparanib program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.